[
  {
    "ts": null,
    "headline": "VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future",
    "summary": "A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves",
    "url": "https://finnhub.io/api/news?id=f5b8dd330fb63b7d7d18eb5bdce1105353fcf5a2c359fcfad59cf458e8d91ad4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763656380,
      "headline": "VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future",
      "id": 137562926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves",
      "url": "https://finnhub.io/api/news?id=f5b8dd330fb63b7d7d18eb5bdce1105353fcf5a2c359fcfad59cf458e8d91ad4"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug",
    "summary": "Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.",
    "url": "https://finnhub.io/api/news?id=98c70c7c5eeab834aba20473a0aa990bd63730604dc53e9390a9531a7403f531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763656200,
      "headline": "VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug",
      "id": 137562927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.",
      "url": "https://finnhub.io/api/news?id=98c70c7c5eeab834aba20473a0aa990bd63730604dc53e9390a9531a7403f531"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit",
    "summary": "STORY: Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's disease.Two trials have been described by Novo as a \"lottery ticket\".They're testing its older diabetes pill that has the same active ingredient as Ozempic and Wegovy in thousands of people with mild Alzheimer's.The goal is to decrease patients' rate of cognitive decline by at least 20%.Alzheimer's experts say success would usher in a convenient new treatment to slow progression in a condition that affects 50 million people globally.Researchers expect to glean important clues for future study into how and why these types of drugs, which include Eli Lilly’s Zepbound and Mounjaro, may be useful against the disease.There are currently two drugs approved for slowing Alzheimer's by removing amyloid from the brain.They are Lilly's Kisunla,  Leqembi from Eisai, and Biogen.They were shown in clinical trials to slow disease progression by close to 30%.Although they also carry the risk of serious side effects and require regular scans.Novo is slated to present its results on December 3rd, although it could announce some data before then.",
    "url": "https://finnhub.io/api/news?id=ca8b7a730a85a6cfab818628a7c17f54bca4458d8f4a8c7d92e940c4542b50d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763650783,
      "headline": "Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit",
      "id": 137556346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's disease.Two trials have been described by Novo as a \"lottery ticket\".They're testing its older diabetes pill that has the same active ingredient as Ozempic and Wegovy in thousands of people with mild Alzheimer's.The goal is to decrease patients' rate of cognitive decline by at least 20%.Alzheimer's experts say success would usher in a convenient new treatment to slow progression in a condition that affects 50 million people globally.Researchers expect to glean important clues for future study into how and why these types of drugs, which include Eli Lilly’s Zepbound and Mounjaro, may be useful against the disease.There are currently two drugs approved for slowing Alzheimer's by removing amyloid from the brain.They are Lilly's Kisunla,  Leqembi from Eisai, and Biogen.They were shown in clinical trials to slow disease progression by close to 30%.Although they also carry the risk of serious side effects and require regular scans.Novo is slated to present its results on December 3rd, although it could announce some data before then.",
      "url": "https://finnhub.io/api/news?id=ca8b7a730a85a6cfab818628a7c17f54bca4458d8f4a8c7d92e940c4542b50d2"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Eli Lilly (LLY) is a Strong Growth Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=efc588e808767d9a68285ff6ef242555067043dab9d9a43bcdc614ab861c3b1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763649903,
      "headline": "Here's Why Eli Lilly (LLY) is a Strong Growth Stock",
      "id": 137562929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=efc588e808767d9a68285ff6ef242555067043dab9d9a43bcdc614ab861c3b1b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Will Wegovy And Pipeline Spark Rally?",
    "summary": "Discover 5+ factors making Novo Nordisk a strong long-term stock pick despite market skepticism.",
    "url": "https://finnhub.io/api/news?id=194d7708f918ec1df5a237a1ccc54ff69f6767151c5969241794ff371de89988",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643080,
      "headline": "Novo Nordisk: Will Wegovy And Pipeline Spark Rally?",
      "id": 137561050,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311809105/image_1311809105.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover 5+ factors making Novo Nordisk a strong long-term stock pick despite market skepticism.",
      "url": "https://finnhub.io/api/news?id=194d7708f918ec1df5a237a1ccc54ff69f6767151c5969241794ff371de89988"
    }
  },
  {
    "ts": null,
    "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
    "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
    "url": "https://finnhub.io/api/news?id=be5320fdeae70f568f8619c0ea2b0af9be5f204d2cf7960957e2d60c174eb756",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763635860,
      "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
      "id": 137554467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
      "url": "https://finnhub.io/api/news?id=be5320fdeae70f568f8619c0ea2b0af9be5f204d2cf7960957e2d60c174eb756"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Potential Winner With Value Trap Risks",
    "summary": "Novo Nordisk: Potential Winner With Value Trap Risks",
    "url": "https://finnhub.io/api/news?id=8e692a87bf3aa8498f707c36d2367f0e2ffce98613a5ee4d895e5078065911e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763633387,
      "headline": "Novo Nordisk: Potential Winner With Value Trap Risks",
      "id": 137555977,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8e692a87bf3aa8498f707c36d2367f0e2ffce98613a5ee4d895e5078065911e5"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly?",
    "summary": "Novo Nordisk just addressed a problem that has prevented some from taking these drugs.",
    "url": "https://finnhub.io/api/news?id=f7d0d70de3ad9493945310fe21371e61dc5eb269ccbb4fc4ce5112cb2ef04bb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763628000,
      "headline": "Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly?",
      "id": 137553858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk just addressed a problem that has prevented some from taking these drugs.",
      "url": "https://finnhub.io/api/news?id=f7d0d70de3ad9493945310fe21371e61dc5eb269ccbb4fc4ce5112cb2ef04bb1"
    }
  },
  {
    "ts": null,
    "headline": "Obesity-drugmaker Novo Nordisk helps drive Denmark's fastest growth in years",
    "summary": "Denmark's GDP grew by the most in four years as Novo Nordisk continues to boost the small Nordic country's economy.",
    "url": "https://finnhub.io/api/news?id=cdf9536eddd264b1e222f7756f510e56957c3a7c737d36814f5568f23106933d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763627014,
      "headline": "Obesity-drugmaker Novo Nordisk helps drive Denmark's fastest growth in years",
      "id": 137559087,
      "image": "https://image.cnbcfm.com/api/v1/image/108004562-1749663845854-108004562-1720707230247-gettyimages-2160946786-20090101240711-99-704451.jpg?v=1763643184&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Denmark's GDP grew by the most in four years as Novo Nordisk continues to boost the small Nordic country's economy.",
      "url": "https://finnhub.io/api/news?id=cdf9536eddd264b1e222f7756f510e56957c3a7c737d36814f5568f23106933d"
    }
  },
  {
    "ts": null,
    "headline": "IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors",
    "summary": "PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director. Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical companies.",
    "url": "https://finnhub.io/api/news?id=6b2d8a0b17da90e870511e5f1216cb00dc0751d2ea542be2703a712ce9a690fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763625600,
      "headline": "IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors",
      "id": 137553859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director. Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical companies.",
      "url": "https://finnhub.io/api/news?id=6b2d8a0b17da90e870511e5f1216cb00dc0751d2ea542be2703a712ce9a690fb"
    }
  },
  {
    "ts": null,
    "headline": "How do Big Pharma employees rate their CEOs?",
    "summary": "There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.",
    "url": "https://finnhub.io/api/news?id=6549922a2b88bb3e8c5c9c9e0be9c6a1375004df78f576cb89ed4effdd358b06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763624979,
      "headline": "How do Big Pharma employees rate their CEOs?",
      "id": 137556349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.",
      "url": "https://finnhub.io/api/news?id=6549922a2b88bb3e8c5c9c9e0be9c6a1375004df78f576cb89ed4effdd358b06"
    }
  },
  {
    "ts": null,
    "headline": "Truist Securities Maintains Eli Lilly and (LLY) Buy Recommendation",
    "summary": "Truist Securities Maintains Eli Lilly and (LLY) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=33fa3841e5f7ee04bdf83adf5d3f8797c25f6929253c38f7fcd007e81a39b346",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763597052,
      "headline": "Truist Securities Maintains Eli Lilly and (LLY) Buy Recommendation",
      "id": 137550714,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=33fa3841e5f7ee04bdf83adf5d3f8797c25f6929253c38f7fcd007e81a39b346"
    }
  }
]